Beta

Onkure therapeutics, inc.OKUR.US Overview

US StockHealthcare
(No presentation for OKUR)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

OKUR AI Insights

OKUR Overall Performance

OKUR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OKUR Recent Performance

4.61%

Onkure therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

OKUR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check OKUR's Trend

OKUR Key Information

OKUR Valuation Metrics

OKUR Profile

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Price of OKUR

OKUR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OKUR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.51
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is OKUR's latest earnings report released?

    The most recent financial report for Onkure therapeutics, inc. (OKUR) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OKUR's short-term business performance and financial health. For the latest updates on OKUR's earnings releases, visit this page regularly.

  • How much cash does OKUR have?

    At the end of the period, Onkure therapeutics, inc. (OKUR) held Total Cash and Cash Equivalents of 59.05M, accounting for 0.95 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is OKUR's EPS continuing to grow?

    According to the past four quarterly reports, Onkure therapeutics, inc. (OKUR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.99. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OKUR?

    Onkure therapeutics, inc. (OKUR)'s Free Cash Flow (FCF) for the period is -11.52M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 45.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OKUR?

    The latest valuation data shows Onkure therapeutics, inc. (OKUR) has a Price-To-Earnings (PE) ratio of -0.81 and a Price/Earnings-To-Growth (PEG) ratio of 0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.